A replication competent foamy virus derived retroviral vector expressing suicide genes has been constructed and characterized in vitro. Here we used vectors expressing the purine nucleoside phosphorylase (FOV-7/pnp), the nitroreductase (FOV-7/ntr), or the thymidine kinase (FOV-7/tk) suicide gene in an in vivo athymic (nude) mice/human glioblastoma tumor model. Gliomas were induced by subcutanous injection of U87 tumor cells. The virus vector was injected when the tumor became visible. Mice with vector virus-injected tumors were treated with the respective prodrug. The treatment resulted in significant inhibition of tumor growth. Surprisingly, in mice with vector virus-injected tumors without prodrug treatment a similar suppression of tumor growth was observed. In 65% (pnp vector), 75% (ntr vector) and 37% (tk vector) of these mice the tumors stopped growing or vanished and the animals remained tumor free for the 25 weeks of the experiment, whereas all mice of the control groups had to be killed because of the tumor growth. In control experiments, the suppression of tumor growth could also be observed when wild-type foamy virus was injected instead of the suicide gene-transducing vectors. Similar results were obtained using the nude mice/G59 human glioblastoma tumor model. In conclusion, the experiments demonstrate an oncolytic activity of foamy virus replication in a nudemice glioblastoma xenograft tumor model. The analysis of vector virus DNA by PCR revealed that the vector persisted in different organs of the animals irrespective of the use of a prodrug or the elimination of a tumor. Cancer Gene Therapy (2005) 12, 947-953.
G ene therapy of malignant human glioma with a retroviral packaging cell line, which produced a murine retroviral vector capable of transducing recipient tumor cells positive for the herpes simplex virus thymidine kinase (tk) followed by administration of ganciclovir (the ''suicide'' gene approach) has attracted a lot of scientific and public attention, because initial results in animal models were encouraging. 1 However, human clinical trials did not meet with great success. 2, 3 The limited spread of the tk-transfering vector to malignant cells outside the close vicinity of the injection site was responsible for this failure. Consequently, replicating or conditionally replicating vector systems were developed, which either transfer a suicide gene or exhibit oncolytic activity upon replication. [4] [5] [6] [7] Foamy viruses (FV) are a subfamily of retroviruses, which follow a unique replication pathway distinct from orthoretroviruses and with many analogies to the hepadnaviral replication strategy. 8 The infection of natural hosts by FV is regarded to be nonpathogenic. 9 However, FV DNA was detected in every organ of infected animals that has been looked at. 9 The viral receptor appears to be very widespread, which also points to a broad tissue spectrum of FV. 10 Unlike lentiviruses and similar to murine leukemia virus FV require dividing cells for integration and replication, 11 ,12 which appears to be a requisite of a retrovirus vector to be used in cancer therapy.
Humans are not natural hosts of FV and a pre-existing immunity is not of concern. 13 However, humans can be readily and persistently infected by FV of nonhuman primate origin. 13 The infection is not transmitted to other humans, even by intimate contact, and no disease could be associated with these rare zoonotic transmissions. 13 The complete proviral genome of the so-called prototypic FV (PFV), which is probably a virus isolated from human tissue following trans-species infection by a chimpanzee virus, 14, 15 has been cloned, sequenced, and functionally studied. 16 FV posses two open reading frames (orf) in addition to gag, pol, and env. 16 The first accessory orf encodes the transcriptional transactivator (tas), which is essential for virus replication. The second orf is expressed predominantly from a multispliced mRNA to give rise to the Bet protein (see below). Bet is of ill-defined function and not required for replication in a majority of cell types. 16 We have previously constructed a variety of FV vectors, which are deleted in the second accessory orf and are able to express foreign genes by different mechanisms using either heterologous or authentic FV promoters. 17 In a follow-up study we used the replicationcompetent pFOV-7 vector type for the generation of various suicide gene-transducing viruses. 18 Here we constructed an additional suicide gene-expressing vector (pFOV-7/ntr) and analyzed three virus-suicide gene combinations for their ability to suppress tumor growth in a human glioma xenograft mouse model.
Materials and methods

Recombinant DNA
Established techniques in molecular biology were used for work with recombinant DNA. 19, 20 The parental infectious molecular FV clone pHSRV2, the replication-competent FV vector pFOV-7, and the suicide gene-transducing recombinant vectors pFOV-7/tk, expressing herpes simplex virus thymidine kinase, and pFOV-7/pnp, expressing Escherichia coli purine nucleoside phosphorylase, have been described previously. 18 The ntr gene was PCR amplified from JM101 bacteria using the primers #420 (5 0 GGGCCCGGGAATGGATATCATTTCTGTCGCC TTA) and #421 (5 0 GGGCCCGGGTTACACTTCGGTT AAGGTGATGTT). The amplimer was digested with SmaI and inserted into a SmaI cut pBluescript vector. Following DNA sequencing to verify the correct ntr gene sequence the 0.66 kb SmaI fragment was inserted into SmaI cut pFOV-7 in-frame to the deleted bet coding sequence as described previously for other pFOV-7 constructs. 18 This resulted in the plasmid pFOV-7/ntr (Fig 1) .
Cells and viruses
Virus was generated by calcium phosphate coprecipitation-mediated transfection of baby hamster kidney cells (BHK-21) and was abbreviated with the plasmid name lacking the 'p'. Stock virus was grown on BHK-21 cells and was prepared from intracellular virus by two cycles of freezing/thawing. After clearance by low-speed centrifugation (1 min at 150 g) the virus lysate was stored at À801C. A mock lysate was prepared in an identical fashion from uninfected BHK-21 cells. Titration of virus was performed by a blue cell assay using BHK/LTRlacZ indicator cells and virus titers were expressed as focusforming units (FFU) as described. 17 The glioma cell lines U87 and G59 have been described previously. 21, 22 They were grown in Dulbecco's-modified Eagle's minimal essential medium (DMEM) supplemented with 10% fetal calf serum, glutamine and antibiotics. Susceptibility testing of cell cultures to FV infection and cell survival following infection with vectors FOV-7/tk, FOV-7/pnp, and FOV-7/ntr and prodrug treatment was performed as described previously. Figure 1 Schematic representation of the vectors used in this study. All vectors are based on the molecular PFV clone pHSRV2. 17 For the generation of the pFOV vector system the orf-2 genomic region was deleted just downstream of the tas orf up to the polypurine tract in front of the 3 0 LTR. In the pFOV-7 replicating foamy vector the gene of interest is inserted in frame to orf-2. 17 It is initially expressed as a fusion protein to the truncated Bet protein. 17 The self-cleaving 2A proteinase sequence of FMDV (2A-PRT) was introduced to facilitate the cleavage of the fusion partners. Cells infected by these vectors in vitro showed good expression of functional active recombinant proteins. 17, 18 Experimental therapy of allogeneic solid tumors M Heinkelein et al Prodrugs Gancyclovir (Cymeven from Roche) served as prodrug for herpes simplex virus tk. The pnp prodrug 9-D-2-deoxyerythropentofuranosyl-6-methylpurine (MePdR) 23 was synthesized via coupling of triacetyl-D-ribofuranose with silylated N-methylpurine in the presence of trimethylsilyltrifluoromethanesulfate. Deacetylation was achieved with ammonia in ethanol and the resulting mixture of nucleosides was separated into the pure a-and b-anomer by combination of conventional silica gel column chromatography, crystallization and preparative HPLC. The isolated a-and b-anomers had greater than 98% purity by HPLC and were identified by 2D-NOESY NMR spectroscopy. The ntr prodrug CB1954 was from Sigma.
Animal experiments
Outbread nude mice were purchased from a commercial breeder (Harlan and Winkelmann). Eight-to 10-week-old mice were injected subcutaneously with 7 Â 10 5 glioma cells into the back flank. When the tumors reached a diameter of 4-6 mm (usually within 20-30 days following injection) they were infected with the virus (four injections of 5-10 Â 10 5 FFU each within 1 week) in a volume of 100 ml by direct injection into the tumor mass. Mice with vector virus injected tumors and control mice were treated with the respective prodrug by intraperitoneal injection 14 days after the first vector injection (FOV-7/pnp, b-MePdR prodrug at 20 mg/kg once daily for 7 days; FOV-7/ntr, two CB1954 prodrug injections of 80 mg/kg 7 days apart; FOV-7/tk, gancyclovir prodrug administration at 30 mg/kg daily for 10 days). The animals were followed for up to 25 weeks and were inspected and weighted at least twice weekly. Mice were killed when the tumor volume exceeded 2 ml. In mice, which were further analyzed by PCR or histopathology, part of the tumor and the organs were frozen at À801C for analysis and/or organs were fixed in 4% formaldehyde in PBS.
PCR analysis
DNA was extracted from tumors and organs using the Qiamp tissue kit (Qiagen). One microgram of DNA was analyzed by nested PCR as described previously. 15, 24 To detect the vector DNA LTR-specific primers were used (#314, 5 0 aaggtgggaaagtggatattgtgacc; #315, 5 0 cagatgga cccttctaaaagccacag; #316, 5 0 tccctagtggataaaaagctgtctgc; #317, 5 0 cttcaccttcccacgggcaactttag). The amplimers were run on ethidium bromide-containing agarose gels and visualized under UV-light.
Results
Construction and in vitro characterisation of replicating foamy virus vectors expressing suicide genes
The second accessory orf of PFV is preferentially expressed from a multispliced RNA that joins a tas exon to the complete orf-2. 16 This splicing event gives rise to the 60 kDa Bet protein. Bet is the most abundant viral protein in infected cells (our unpublished observation). The pFOV-7 vector was made by deleting the orf-2 genomic region just downstream of the tas orf up to the polypurine tract in front of the 3 0 long terminal repeat (LTR) (Fig 1) . A small polylinker was introduced into the deletion to facilitate insertion of foreign genes, which are expressed as fusion proteins to the C-terminally truncated Bet protein. An additional oligonucleotide was introduced upstream of the polylinker sequence coding for the self-cleaving foot-and-mouth disease virus (FMDV) 2A protease. 25 In the resulting vector the foreign gene is initially expressed as a fusion protein to the truncated Bet protein. The presence of the FMDV 2A protease between the two fusion partners results in their separation via autocatalytic cleavage. 17 Recombinant viruses for suicide gene therapy were constructed by inserting the tk, pnp, and ntr genes into pFOV-7. pFOV-7/tk and pFOV-7/pnp have been characterized previously.
18 pFOV-7/ntr was also shown to specifically kill virus-infected cells in vitro following addition of the respective prodrug (data not shown). The stability of the inserted suicide gene during 10 cellfree passages could be demonstrated for the FOV-7/pnp and the FOV-7/ntr viruses by immunoblot and PCR, whereas the deletion of the tk insert in the FOV-7/tk virus was detected after three cell-free passages of the virus (Rethwilm 18 and data not shown).
Inhibition of tumor growth in the nude-mice/human glioblastoma xenograft model
Tumors were induced in nude mice by subcutanous injection of U87 glioma cells. The viral vectors were injected directly into the tumors when the tumor diameter was 4-6 mm (four injections of 5-10 Â 10 5 FFU within 1 week). Mice with vector virus-injected tumors were treated with the respective prodrug 14 days after the first vector injection.
Four groups of animals consisting of eight to nine animals per group were analyzed for each vector prodrug combination. Group one received only glioma cells, in the second group the tumors were treated by prodrug, in the third group the tumors were infected with virus vector, and in group four the tumors were infected with virus vector, which was followed by the respective prodrug treatment. All control animals of group one had to be killed because of tumor growth. Using the pnp prodrug b-MePdR 44% of the mice died because of severe toxic side effects of the prodrug treatment, consisting of gastrointestinal bleeding, anemia, and body weight loss. The histopathological analysis revealed a severe depletion of splenic and bone marrow tissue (data not shown). These toxic side effects were observed in b-MePdRtreated animals irrespective of the vector application, although the symptoms were less pronounced in mice receiving only the prodrug. The ntr and tk prodrugs were tolerated well. Treatment of the tumors with the suicide gene-transferring vectors together with the respective prodrug resulted in significant inhibition of tumor Figure 2 these data are summarized and expressed as survival times of animals. There was no difference between the expression of the results as survival times or tumor growth. In treated mice tumor growth was stopped and in over 30% (pnp vector), 60% (ntr vector), and 25% (tk vector) the tumors could be eliminated and did not return for the duration of the experiment. In mice with vector virus-injected tumors a suppression of tumor growth was also observed in the absence of prodrug treatment. Surprisingly, the effect of viral elimination of tumor cells was slightly better in the absence of prodrug treatment than in the presence (Fig 2) . While this difference in ntr vector (75% survival without prodrug treatment compared with 60% survival in the group four animals) and tk vector-treated animals (37% survival in group three compared with 25% survival in group four) was statistically not significant, because it affected only one or two animals, the 65% survival in the pnp vector group differed markedly from the 32% survival in the group, which received pnp vector and the respective prodrug. However, as already stated above we attribute this finding to the toxic side effects of the prodrug b-MePdR.
In summary, we demonstrated a significant antitumor activity of the foamy virus vectors in this glioblastoma xenograft model, which appeared to be independent of the kind of the inserted suicide gene and prodrug therapy.
Inhibition of tumor growth by wild-type FV
To find out, whether the replication of unmodified FV also had a oncolytic effect, we infected U87 cell-generated tumors with wild-type FV derived from a molecular clone. Tumors were induced as described above. Wild-type FV or mock virus preparations were injected into the tumors when the diameter reached 4-6 mm (four injections of 5-10 Â 10 5 FFU within 1 week). A third group of mice received only tumor cells and remained untreated. Six to eight animals per group were analyzed (Fig 3) . The untreated or mock-injected animals had to be killed because of tumor growth within the first 80 days of the experiments, whereas 36% of animals infected with FV survived and stayed tumor free for 25 weeks (Fig 3) . Thus, antitumour activity was seen when the tumors were infected with wild-type FV.
Inhibition of tumor growth by replicating foamy virus vectors in the G59 glioma model
To analyze whether the oncolytic effect of FV is restricted to U87 tumors or can be generalized we induced tumors in athymic mice by subcutaneous injection of G59 glioma cells. We studied two groups of animals each consisting of six to eight mice. One group received G59 cells only and one group received in addition FOV-7/pnp virus vector, but no prodrug treatment using the same protocol as described above for U87 cells. G59-induced tumors grew very slowly and no mice had to be killed because of tumor growth during the course of the experiment (150 days). However, in virus vector-treated animals the tumor growth stopped and the tumors vanished (Fig 4) . Thus, the oncolytic effect of FV vectors appears to be a more general phenomenon and not restricted to a particular tumor cell line. Furthermore, the slowness of tumor development and elimination observed in this experiment clearly shows that active vector replication was required for tumor elimination and not toxic effects of the initial inoculums.
Analysis of vector spread in treated animals
To analyze the vector spread in treated animals, 12 vector-injected animals, which received no prodrug treatment, were analyzed for the presence of FV DNA by PCR. FV DNA was detected in all tumors and also in other organs of vector-treated mice (Table 1) . This finding was independent of the type of vector used and indicated that vector replication is probably not restricted to the tumor. Persistence of vector DNA was also detected in vector-treated tumor-free survivors, which received prodrug treatment. Vector DNA was found to persist in two of three pnp-, three of six ntr-, and in one of one tktreated animals, which were analyzed. Since the period between the end of prodrug treatment and scarification of the animals was longer than 10 days, it can be concluded that vector virus persisted independently of pharmacological treatment. This is of particular interest, because the prodrug treatment should result in vector elimination. It may be an inherent problem of replicating retroviral vectors that genes without essential function for viral replication become deleted. 
Discussion
The concept of using suicide gene-transducing viral vectors to selectively kill tumor cells in vivo has been intensively followed over several years. However, due to drawbacks in clinical studies with these vectors new approaches were followed. Among these the use of oncolytic viruses (OV) has become increasingly popular. 6 OVs can be either genetically modified viruses, that is attenuated, with a tumor cell-specific tropism, or tumor cell-speciifc promoters, or certain strains of wild-type viruses. 6 Here we tried to combine the suicide gene approach with a replication-competent vector derived from a virus belonging to the family of Retroviridae in order to enhance the tumor cell killing activity and the vector spread in the tumor tissue.
FVs belong to a poorly characterized subfamily of retroviruses with no pathogenicity in natural animal or accidental human infections. 26 Their receptor is unknown and they replicate in a wide range of primary cells and adapted cell lines. 26 However, it has been shown that active cell division is required for FV replication and vector transduction. 11 Thus, any selectivity for tumor cells is probably due to this particular feature of FVs.
Surprisingly, we found that the administration of the respective prodrug after allowing vector replication was not advantageous in antitumor growth activity compared with vector replication alone. While this was apparent for all three suicide gene-transducing vectors, differences between the individual constructs were noted.
The FOV-7/pnp and b-MePdR-treated animals survived significantly shorter than only the FOV-7/pnptreated mice, because of the severe toxic side effects of the prodrug, which have to our knowledge not been described in detail yet and which were also seen when mice were treated with the prodrug only.
With the FOV-7/tk virus deletions were already seen upon cell culture replication. 18 Thus, a reduced survival of mice, which were treated with this vector in the absence of prodrug compared with mice treated with the other two vectors, was probably due to the weaker replication competence in vivo.
When the virus from which the vectors were derived was analyzed for its oncolytic activity, we found it also exerts an oncolytic activity. Slight differences in the replication competence between the HSRV2 and the vector viruses [15] [16] [17] may be responsible for the reduced capacity of HSRV2 to cure tumor-bearing mice.
Tumor growth in animals implanted with G59 cells was so slow that only the reduction in tumor mass could be measured in FV vector-treated mice compared with untreated animals. Our initial observation made in the U87 xenograft model was fully supported using this glioma xenograft animal model.
However, our results demonstrate that vector replication is not restricted to the tumor. Even in mice successfully treated with vector and the respective prodrug, the virus was not eliminated from the host. It was found to reside in various mouse tissues including the gonads. Although there is so far no evidence that FV become pathogenic and spread among humans, 13 the risk of adaptation and development of a new human retroviral infection cannot be excluded. 27, 28 The AIDS pandemic arose by trans-species transmission of monkey and ape retroviruses to humans. 29 Bearing this risk in mind we regard it to be not opportune to proceed with this approach into the direction of clinical studies in humans.
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